H.B. Fuller Company (FUL)
NYSE: FUL · Real-Time Price · USD
62.00
-0.85 (-1.35%)
Apr 28, 2026, 12:50 PM EDT - Market open

H.B. Fuller Company Earnings Call Transcripts

Fiscal Year 2026

  • AGM 2026

    The meeting covered director elections, auditor ratification, and executive compensation, with all proposals passing. No shareholder questions were submitted during the Q&A session.

  • Q1 2026 saw margin expansion and profit growth despite a 6.6% organic revenue decline, driven by pricing and cost actions. Guidance was raised on pricing power and market share gains amid global supply chain disruptions, with a focus on share repurchases and operational resilience.

Fiscal Year 2025

  • Q4 saw strong margin expansion and double-digit EPS growth despite revenue declines, with EBITDA at the top end of guidance. 2026 outlook calls for flat to modest revenue growth, continued margin gains, and robust M&A activity, even as macro headwinds persist.

  • Investor Day 2025

    The company is targeting over 20% EBITDA margins by 2028, driven by Project Quantum Leap, disciplined M&A, and a shift toward higher-value segments. Financial guidance includes 5%+ revenue growth and strong cash generation, with a focus on innovation, operational excellence, and portfolio optimization.

  • Q3 saw margin expansion and double-digit EPS growth despite economic headwinds, with strong execution in pricing, cost control, and portfolio optimization. Guidance for 2025 was tightened, with EBITDA and EPS growth expected, though cash flow is temporarily reduced due to higher inventory for footprint optimization.

  • Q2 2025 saw strong margin expansion and robust execution, with adjusted EBITDA up 5% and EPS up 5% year-on-year. Full-year guidance was raised, despite ongoing economic and tariff uncertainties, as portfolio shifts and cost actions drive continued profit growth.

  • AGM 2025

    The meeting covered director elections, auditor ratification, executive compensation, and incentive plan amendments, with all proposals approved. No shareholder questions were received during the Q&A session.

  • Q1 saw 1.9% organic revenue growth and strong share gains in HHC and China, but higher raw material costs compressed margins. Guidance for 2025 is unchanged, with EBITDA expected to grow 1%-5% and a focus on share buybacks over M&A due to elevated leverage.

Fiscal Year 2024

Fiscal Year 2023

Fiscal Year 2022

Fiscal Year 2021

Fiscal Year 2020

Fiscal Year 2019

Fiscal Year 2018

Powered by